Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
TEM Stock Chart & Stats
$77.21
-$0.17(-0.45%)
At close: 4:00 PM EST
$77.21
-$0.17(-0.45%)
Day’s Range― - ―
52-Week Range$31.36 - $104.32
Previous CloseN/A
Volume1.41M
Average Volume (3M)6.27M
Market Cap
$13.74B
Enterprise Value$14.70B
Total Cash (Recent Filing)$759.64M
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)―
Beta3.09
Next Earnings
Mar 02, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding172,863,460
10 Day Avg. Volume5,585,067
30 Day Avg. Volume6,269,175
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)71.82
Price to Sales (P/S)5.84
P/FCF Ratio-19.16
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue13.30
Enterprise Value/Gross Profit21.67
Enterprise Value/Ebitda-163.81
Forecast
1Y Price Target
$90.18Price Target Upside16.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company had a strong cash position with $764.3M in cash and investments at the end of September 2025.
Revenue GrowthRecord performance in 3Q25 with total revenue showing 84.7% year-over-year growth and outperforming projections.
Strategic CollaborationsThe collaboration with Whitehawk Therapeutics aims to leverage Tempus’ real-world dataset to advance biomarker-driven research and support the development of antibody drug conjugates (ADC) cancer treatments.
Bears Say
Growth OutlookThere is an expectation that the company's growth will slow down in 2026 unless a major acquisition occurs.
Operating ExpensesOperating expenses increased sequentially from 1Q25 to 3Q25, potentially impacting future profitability.
Stock ValuationAlthough business fundamentals remain constructive, the stock is considered more fairly valued at a high multiple, leading to a downgrade to Hold.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $31.36 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $13.74B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Mar 02, 2026 which is in 92 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Nov 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.172 by $0.062.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.04.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 172,863,460 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.172. Following the earnings report the stock price went down -2.639%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
Tempus AI, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$90.18 (16.80% Upside)
$90.18 (16.80% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 73%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 220.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.16%
12-Months-Change
Fundamentals
Return on Equity
-72.61%
Trailing 12-Months
Asset Growth
134.78%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in Genomics and significant achievements like positive adjusted EBITDA and successful data licensing deals. However, there were challenges such as the disruption caused by changes in the sales force and costs associated with the Paige acquisition. Overall, the positive achievements and strong growth trajectory indicate a healthy business outlook.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$90.18
▲(16.80% Upside)
Technical Analysis
Ownership Overview
40.78% Insiders
7.20% Mutual Funds
16.48% Other Institutional Investors
22.23% Public Companies and Individual Investors